OBJECTIVES. Mexico has risen to the occasion and has achieve that HIV drugs can be available to all people detected with HIV infection who requires them. The objective of this study is to develop a budget impact analysis based on a decicion three model, which estimates the incremental costs associated with the treatments recommended by the Mexican aids plan guidelines for preferent no coformulated initial antiretroviral therapy in naïve HIV-infected adults in Mexico.

METHODS. A Budget Impact Analysis was developed. Cost of initiating treatment with an ART regimen was defined as the costs of ART and for an expected cohort of 122 naïve patients. The payer perspective (Mexican National Health System) was applied considering only differential direct costs. A univariate sensitivity analysis was conducted to assess the robustness of the base case results. No discount rate was considered (analysis within one year). The costs are presented in USD. Preferente no coformulated initial antiretroviral therapies compared in this study, acording to the ART Mexican Guidelines, are DGT + TDF/FTC 70% share, DGT + TDS/FTC 30% share (in the current situation) and DGT + TAF/FTC (in the new situation, 3 shares are analyzed: 30%, 50% y 70%).

RESULTS. The total impact is $277,617.34 (95% CI, ±$27,761.73 ). In the new situation the costs when DGT+TAF/FTC = 30% the total cost is $291,842.20 (95% CI, ± $29,184.22), when DGT+TAF/FTC = 50% the cost is $298,026.92 (95% CI, ± $29,802.69 ), finally when DGT+TAF/FTC = 70% the expected cost is $304,211.64 (95% CI, ± $30,421.16 ).

CONCLUSIONS. Adding DGT+TAF/FTC to ART regimen, resulted in a cost increase of $20,409.58 per year vs the current situation. The 2 ARV regimens in the current scenario are cost-saving when compare to the new regimen listed in the national aids plan recommended guidelines for preferent no coformulated initial ARV.